Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.55 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.55 |
| ▸ | MMP2 | P08253 | 1/20 | 0.54 |
| ▸ | MMP12 | P39900 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.49 |
| ▸ | APP | P05067 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3685598 | 1.00 | FFAR1 (0.55) | FFAR1FFAR4MMP2MMP12KCNH2 | |
| SCHEMBL5886652 | 0.90 | FFAR1 (0.63) | FFAR1FFAR4MMP2MMP12KCNH2 | |
| SCHEMBL18357105 | 0.85 | ACHE (0.48) | FFAR1FFAR4MMP2MMP12KCNH2 | |
| SCHEMBL19523535 | 0.83 | MAPT (0.63) | FFAR1FFAR4MMP2MMP12APP | |
| SCHEMBL5886550 | 0.83 | KCNH2 (0.59) | FFAR1FFAR4MMP2MMP12KCNH2 | |
| SCHEMBL6719972 | 0.82 | FFAR1 (0.60) | FFAR1FFAR4MMP2MMP12KCNH2 | |
| SCHEMBL6022668 | 0.82 | FFAR1 (0.60) | FFAR1FFAR4MMP2MMP12KCNH2 | |
| SCHEMBL6718627 | 0.82 | FFAR1 (0.60) | FFAR1FFAR4MMP2MMP12KCNH2 | |
| SCHEMBL5886588 | 0.82 | FFAR1 (0.53) | FFAR1FFAR4MMP2MMP12KCNH2 | |
| SCHEMBL5886641 | 0.81 | KCNH2 (0.60) | FFAR1FFAR4MMP2MMP12KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410150-B2 | Inhibitors of carnitine palmitoyltransferase and treating cancer | UNIVERSITY HEALTH NETWORK (CA) | 2013-04-02 | — | — | US | disclosed |
| US-20100105900-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | UNIVERSITY HEALTH NETWORK | 2010-04-29 | — | — | US | disclosed |
| WO-2008109991-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | UNIVERSITY HEALTH NETWORK (CA) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105900-A1 | INHIBITORS OF CARNITINE PALMITOYLTRANSFERASE AND TREATING CANCER | CPT1A, CPT1B, CPT2 | FFAR1 772/4885FFAR4 1269/4885MMP2 961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.